MedTrace Logo

Potential of Stannous Fluoride Toothpaste to Reduce Gum Disease

NCT02750943 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 253

Last updated 2017-10-26

Study results available
· View outcomes & findings →

Summary

This will be a single-center, 12 week, examiner-blind, randomized, stratified (gender and baseline mean whole mouth MGI score), two-treatment, parallel group, clinical study in healthy adult volunteers with moderate gingivitis. This study will evaluate the efficacy of a dentifrice containing 0.454% weight by weight (w/w) stannous fluoride to control gingivitis and gingival bleeding following 12 weeks twice daily brushing, compared to a negative control dentifrice.

Conditions

  • Gingivitis

Interventions

DRUG

Stannous Fluoride

Dentifrice containing 0.454% w/w stannous fluoride

DRUG

Sodium Monofluorophosphate

Dentifrice containing 1000ppm fluoride as sodium monofluorophosphate

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-11-01
Primary Completion
2016-03-01
Completion
2016-03-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02750943 on ClinicalTrials.gov